SOSTDC1
Sclerostin domain-containing protein 1
Protein Summary
May be involved in the onset of endometrial receptivity for implantation/sensitization for the decidual cell reaction Enhances Wnt signaling and inhibits TGF-beta signaling (By similarity). Directly antagonizes activity of BMP2, BMP4, BMP6 and BMP7 in a dose-dependent manner. This gene is a member of the sclerostin family and encodes an N-glycosylated, secreted protein with a C-terminal cystine knot-like domain. This protein functions as a bone morphogenetic protein (BMP) antagonist. Specifically, it directly associates with BMPs, prohibiting them from binding their receptors, thereby regulating BMP signaling during cellular proliferation, differentiation, and programmed cell death. [provided by RefSeq, Jul 2008]
- ENST00000307068
- ENSP00000304930
- ENSG00000171243
- ENST00000396652
- ENSP00000379889
- USAG1
- DAND7
- USAG1
- CDA019
- ECTODIN
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 0.61 | ||
PubMedID | 0.59 | ||
tissue sample | 0.56 | ||
cell type or tissue | 0.48 | ||
phenotype | 0.44 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 79.85 (req: < 5)
Gene RIFs: 23 (req: <= 3)
Antibodies: 148 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 79.85 (req: >= 5)
Gene RIFs: 23 (req: > 3)
Antibodies: 148 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 13
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0